Cargando…

Lung-Protective Effects of Lidocaine Infusion on Patients with Intermediate/ High Risk of Postoperative Pulmonary Complications: A Double-Blind Randomized Controlled Trial

PURPOSE: The non-local anesthetic effects of lidocaine have been widely reported, but there are still few studies on lung protection. We aimed to test the hypothesis that intravenous infusion of lidocaine exerts lung-protective effects in patients at intermediate/high risk of postoperative pulmonary...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xinghe, Guo, Kedi, Zhao, Ye, Li, Tong, Yang, Yuping, Xu, Lingfei, Liu, Su
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004726/
https://www.ncbi.nlm.nih.gov/pubmed/35422611
http://dx.doi.org/10.2147/DDDT.S358609
_version_ 1784686320126263296
author Wang, Xinghe
Guo, Kedi
Zhao, Ye
Li, Tong
Yang, Yuping
Xu, Lingfei
Liu, Su
author_facet Wang, Xinghe
Guo, Kedi
Zhao, Ye
Li, Tong
Yang, Yuping
Xu, Lingfei
Liu, Su
author_sort Wang, Xinghe
collection PubMed
description PURPOSE: The non-local anesthetic effects of lidocaine have been widely reported, but there are still few studies on lung protection. We aimed to test the hypothesis that intravenous infusion of lidocaine exerts lung-protective effects in patients at intermediate/high risk of postoperative pulmonary complications (PPCs) on major abdominal surgery. PATIENTS AND METHODS: Patients ≥18 years, ASA II or III, with intermediate/high risk for PPCs, were included. Patients were randomly assigned into group lidocaine (received a bolus of lidocaine 1.5 mg kg(−1) before the induction of anesthesia, then followed by a continuous infusion of 2.0 mg kg(−1) h(−1) intraoperatively until the end of surgery) or group control (received 0.9% saline in place of lidocaine at the same time points). The incidence of PPCs within 7 postoperative days was measured, defined as a collapsed composite outcome of atelectasis, respiratory infection, pleural effusion, pneumonia, respiratory failure or acute respiratory distress syndrome (ARDS) developed within 7 postoperative days, or hospital discharge, whichever came sooner. RESULTS: Of 200 subjects screened, 195 patients were finally analyzed. Overall, 35.9% (70/195) patients sustained PPCs, which occurred fewer in group lidocaine 25.8% (25/97), compared with group control 45.9% (45/98) (relative risk: 0.56, 95% CI: 0.38 to 0.84; absolute risk reduction: −20.1%; P = 0.003). Considering single PPCs episode, the most common PPC in both groups was atelectasis. The atelectasis incidence was 11.3% (11/97) in group lidocaine, much lower than that in group control 29.6% (29/98) (relative risk: 0.38, 95% CI: 0.20 to 0.72; absolute risk reduction: −18.3%, P = 0.002). However, the incidences of any other PPCs episodes were similar between the two groups. CONCLUSION: Intraoperative intravenous infusion lidocaine could decrease the incidence of PPCs in patients at intermediate/high risk of postoperative pulmonary complications undergoing major abdominal surgery.
format Online
Article
Text
id pubmed-9004726
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-90047262022-04-13 Lung-Protective Effects of Lidocaine Infusion on Patients with Intermediate/ High Risk of Postoperative Pulmonary Complications: A Double-Blind Randomized Controlled Trial Wang, Xinghe Guo, Kedi Zhao, Ye Li, Tong Yang, Yuping Xu, Lingfei Liu, Su Drug Des Devel Ther Original Research PURPOSE: The non-local anesthetic effects of lidocaine have been widely reported, but there are still few studies on lung protection. We aimed to test the hypothesis that intravenous infusion of lidocaine exerts lung-protective effects in patients at intermediate/high risk of postoperative pulmonary complications (PPCs) on major abdominal surgery. PATIENTS AND METHODS: Patients ≥18 years, ASA II or III, with intermediate/high risk for PPCs, were included. Patients were randomly assigned into group lidocaine (received a bolus of lidocaine 1.5 mg kg(−1) before the induction of anesthesia, then followed by a continuous infusion of 2.0 mg kg(−1) h(−1) intraoperatively until the end of surgery) or group control (received 0.9% saline in place of lidocaine at the same time points). The incidence of PPCs within 7 postoperative days was measured, defined as a collapsed composite outcome of atelectasis, respiratory infection, pleural effusion, pneumonia, respiratory failure or acute respiratory distress syndrome (ARDS) developed within 7 postoperative days, or hospital discharge, whichever came sooner. RESULTS: Of 200 subjects screened, 195 patients were finally analyzed. Overall, 35.9% (70/195) patients sustained PPCs, which occurred fewer in group lidocaine 25.8% (25/97), compared with group control 45.9% (45/98) (relative risk: 0.56, 95% CI: 0.38 to 0.84; absolute risk reduction: −20.1%; P = 0.003). Considering single PPCs episode, the most common PPC in both groups was atelectasis. The atelectasis incidence was 11.3% (11/97) in group lidocaine, much lower than that in group control 29.6% (29/98) (relative risk: 0.38, 95% CI: 0.20 to 0.72; absolute risk reduction: −18.3%, P = 0.002). However, the incidences of any other PPCs episodes were similar between the two groups. CONCLUSION: Intraoperative intravenous infusion lidocaine could decrease the incidence of PPCs in patients at intermediate/high risk of postoperative pulmonary complications undergoing major abdominal surgery. Dove 2022-04-08 /pmc/articles/PMC9004726/ /pubmed/35422611 http://dx.doi.org/10.2147/DDDT.S358609 Text en © 2022 Wang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Wang, Xinghe
Guo, Kedi
Zhao, Ye
Li, Tong
Yang, Yuping
Xu, Lingfei
Liu, Su
Lung-Protective Effects of Lidocaine Infusion on Patients with Intermediate/ High Risk of Postoperative Pulmonary Complications: A Double-Blind Randomized Controlled Trial
title Lung-Protective Effects of Lidocaine Infusion on Patients with Intermediate/ High Risk of Postoperative Pulmonary Complications: A Double-Blind Randomized Controlled Trial
title_full Lung-Protective Effects of Lidocaine Infusion on Patients with Intermediate/ High Risk of Postoperative Pulmonary Complications: A Double-Blind Randomized Controlled Trial
title_fullStr Lung-Protective Effects of Lidocaine Infusion on Patients with Intermediate/ High Risk of Postoperative Pulmonary Complications: A Double-Blind Randomized Controlled Trial
title_full_unstemmed Lung-Protective Effects of Lidocaine Infusion on Patients with Intermediate/ High Risk of Postoperative Pulmonary Complications: A Double-Blind Randomized Controlled Trial
title_short Lung-Protective Effects of Lidocaine Infusion on Patients with Intermediate/ High Risk of Postoperative Pulmonary Complications: A Double-Blind Randomized Controlled Trial
title_sort lung-protective effects of lidocaine infusion on patients with intermediate/ high risk of postoperative pulmonary complications: a double-blind randomized controlled trial
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004726/
https://www.ncbi.nlm.nih.gov/pubmed/35422611
http://dx.doi.org/10.2147/DDDT.S358609
work_keys_str_mv AT wangxinghe lungprotectiveeffectsoflidocaineinfusiononpatientswithintermediatehighriskofpostoperativepulmonarycomplicationsadoubleblindrandomizedcontrolledtrial
AT guokedi lungprotectiveeffectsoflidocaineinfusiononpatientswithintermediatehighriskofpostoperativepulmonarycomplicationsadoubleblindrandomizedcontrolledtrial
AT zhaoye lungprotectiveeffectsoflidocaineinfusiononpatientswithintermediatehighriskofpostoperativepulmonarycomplicationsadoubleblindrandomizedcontrolledtrial
AT litong lungprotectiveeffectsoflidocaineinfusiononpatientswithintermediatehighriskofpostoperativepulmonarycomplicationsadoubleblindrandomizedcontrolledtrial
AT yangyuping lungprotectiveeffectsoflidocaineinfusiononpatientswithintermediatehighriskofpostoperativepulmonarycomplicationsadoubleblindrandomizedcontrolledtrial
AT xulingfei lungprotectiveeffectsoflidocaineinfusiononpatientswithintermediatehighriskofpostoperativepulmonarycomplicationsadoubleblindrandomizedcontrolledtrial
AT liusu lungprotectiveeffectsoflidocaineinfusiononpatientswithintermediatehighriskofpostoperativepulmonarycomplicationsadoubleblindrandomizedcontrolledtrial